Headlines about Sanofi (NYSE:SNY) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sanofi earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.4032295845927 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have effected Accern’s analysis:
- Zacks: Analysts Anticipate Sanofi (SNY) Will Post Quarterly Sales of $10.38 Billion (americanbankingnews.com)
- How a new approach to MS landed Peninsula drug maker a potential $800M deal (feeds.bizjournals.com)
- Sanofi (SNY) Expected to Announce Earnings of $0.69 Per Share (americanbankingnews.com)
- Sanofi (SNY) Shares a Buy on Earnings Momentum – Investorplace.com (investorplace.com)
- Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod (finance.yahoo.com)
Sanofi (NYSE SNY) traded down $0.14 during midday trading on Tuesday, hitting $44.50. The company had a trading volume of 64,197 shares, compared to its average volume of 1,533,673. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $113,467.86, a PE ratio of 14.20, a PEG ratio of 2.48 and a beta of 0.88. Sanofi has a 12 month low of $38.45 and a 12 month high of $50.65.
SNY has been the subject of a number of analyst reports. BidaskClub downgraded Sanofi from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cowen and Company restated a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $53.50.
ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Earning Somewhat Positive Media Coverage, Report Shows” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/11/14/sanofi-sny-earning-somewhat-positive-media-coverage-report-shows.html.
In related news, major shareholder Sanofi purchased 105,820 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.00% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.